Compare RXO & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RXO | TLX |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.3B |
| IPO Year | 2022 | 2024 |
| Metric | RXO | TLX |
|---|---|---|
| Price | $28.45 | $8.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 5 |
| Target Price | ★ $29.83 | $19.66 |
| AVG Volume (30 Days) | ★ 3.4M | 281.5K |
| Earning Date | 10-29-2026 | 02-18-2027 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,742,000,000.00 | N/A |
| Revenue This Year | $21.30 | $16.83 |
| Revenue Next Year | $10.66 | $13.81 |
| P/E Ratio | ★ N/A | $150.33 |
| Revenue Growth | ★ 26.20 | N/A |
| 52 Week Low | $11.18 | $6.28 |
| 52 Week High | $29.90 | $13.11 |
| Indicator | RXO | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 58.68 | 33.74 |
| Support Level | $28.14 | $6.28 |
| Resistance Level | $28.68 | $9.83 |
| Average True Range (ATR) | 0.43 | 0.25 |
| MACD | -0.13 | -0.03 |
| Stochastic Oscillator | 63.48 | 0.95 |
RXO Inc is a brokered transportation platform defined by technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.